Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sabizabulin (VERU-111) for hospitalized adults with COVID-19 at high risk for ARDS
2021-001194-24Phase 3Completed
- Sponsor
- Veru Inc.
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Sabizabulin with Placebo (2 arms). Primary endpoint: Proportion of subjects that die on study up to Day 60. Started Sep 2021; status: completed.
02
Drugs
sabizabulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001194-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001194-24.